“My husband has used lasers in his dental office for decades to performs endodontics and surgeries. Our initial unit was the size of a small filing cabinet and sounded like an airplane engine. The benefits we witnessed made all that worthwhile. A year ago he attended a THOR course in Orlando, Florida and came home enthusiastic over the multiple uses beyond dental applications. I then attended a course with him in Phoenix, AZ and caught his enthusiasm.
We are in a rural area where new ideas are usually met with skepticism. THOR has a large and positive internet presence which helps us explain and promote our THOR laser. The support at THOR is exceptional with timely replies and assistance in researching protocols. When a new patient comes and experiences the healing of THOR laser I often hear “will it also treat ‘this’?” so I research it and am pleased when “yes” is the answer. We’re attending another course soon just to keep up with the THOR research.”
Michele Abernathy, RDA
John S Abernathy, DDS
Arkansas, USA
RESULT: After three presentations and much correspondence over a 5 year period we have a recommendation guideline from the National Institute of Health and Care Excellence (NICE) — LLLT for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This means the NHS can start using our treatment on cancer patients to reduce some of the painful side effects of cancer treatments.
“This is the second time I have attended the PBMT training course as I brought my new Licensed Practical Nurse so she could get the training. I was impressed by all the new and current research material that James Carroll presented. He presented well, with lots of humor and made himself available to answer questions. This time he gave the demonstration on how to use the LX2 unit properly – which was much appreciated.
It is an excellent, well thought-out course and the lunch provided was great with a number of gluten-free choices. Having lunch on-site allowed for more time in discussion with other attendees and staff. Since the training, we have increasingly used the PBMT in the Integrative/Functional Medicine practice. There is no shortage of suffering people who do benefit greatly from the THOR LX2 PBMT technology.”
“The THOR unit is absolutely brilliant. Even I cannot believe how fast client recovery rates are and their overall alertness and energy level improvements. Have had success stories including my son-in-law. He is on his feet all day and for 6 years comes home almost in tears each day with swollen feet and nerve end pain. I carried out Dr. Chow’s back pain method and in two treatments he has been pain free for 3 weeks.”
[Scot Faulkner advises global organizations and universities on healthcare reform and innovation. He served as the Chief Administrative Officer of the U.S. House of Representatives. He also served on the White House Staff, and as an Executive Branch Appointee.]
Imagine being successfully treated, painlessly and safely, for a wide range of diseases and conditions. Imagine having a cure for chronic pain.
This revolution in health and wellness is already available and will be celebrated on May 16 as the United Nations’ Annual International Day of Light.
On May 16, 1960, American physicist and engineer, Theodore Maiman, operated the first successful laser, achieving coherent and controllable light waves. This revolutionized manufacturing, communications, and health.
In 1967, Endre Mester in Semmelweis University Budapest, Hungary conducted studies to determine if lasers caused cancer. He shaved the hair from the bodies of mice, divided them into two groups and gave a laser treatment with a low powered ruby laser to one group. They did not get cancer. Instead the hair on the treated group grew back more quickly than the untreated group. The concept of “laser biostimulation” was discovered.
Today, “biostimulation” is known as Photobiomodulation (PBM). It is the process where a specific range of the light spectrum at the right intensity, when directed to the body for the right period of time, can restore the function of stressed cells to normal healthy operation. It is non-invasive, non-toxic, and has no reported side effects.
There are over 32 trillion cells in the human body. Each cell has hundreds of microscopic factories called mitochondria which combine oxygen with nutrients from the blood stream to make the cellular energy called ATP. This energy is used to help the cell live and to conduct its various roles in our body: keeping the heart beating, the brain thinking, the body moving, and the all the other functions that keep us alive and healthy.
Mester’s discovery was an epiphany. If specific light band waves can help cells to regrow hair, can they wake-up cells to do other things? Now over five-hundred human clinical trials and 4,000 laboratory studies have shown the answer to be an overwhelming YES!
PBM is now a common veterinary treatment for improving the lives of animals suffering from hip dysplasia and kidney failure. Throughout the world, forward thinking Doctors and Dentists are using PBM to successfully treat Oral Mucositis (side effect from chemotherapy), Dry Macular Degeneration, Multiple Sclerosis, Parkinson’s Disease, Lyme Disease, and diabetic wounds. It also reduces pain and inflammation in various orthopedic conditions such as tendonitis, neck pain, low back pain, and carpal tunnel syndrome.
Chronic pain costs Americans over $635 billion a year in additional healthcare costs and lost productivity. PBM is used for recovery and endurance by champion athletes. At the 2016 Rio Olympics, many Nike sponsored athletes used a whole body PBM product called NovoTHOR to help them train, recover, and win more medals. This led NFL, MLB, NHL and NBA teams to add “light beds” to their training regime.
A growing number of doctors and public health officials are exploring PBM therapy as an alternative pain treatment to Opioids. This may help solve the addiction crisis facing America.
If PBM is so effective, why is not everywhere?
Outside of the U.S. it is. Australia, Canada, England, the European Union, and NATO all recognize PBM, promote its use, and accept insurance coverage. The Food and Drug Administration (FDA) is slowly moving towards regulatory clearances for PBM light equipment to officially treat diseases and conditions. Currently, the FDA labels PBM devices in the basic category of infrared or heat lamps.
Until the FDA moves forward, U.S. insurance companies, except for a few BCBS affiliates, refuse to reimburse for PBM treatments. They remain a solid wall of resistance.
Medicare and Medicaid refuse to reimburse for PBM treatments. Federal Officials have labeled PBM “mumbo jumbo” and declared its successes “placebo effect”.
The International Day of Light is an opportunity to alert everyone who could benefit from PBM therapy of its existence and promise. It is a time to ask public officials about ways to bring PBM into the mainstream of American healthcare. It is a time to ask your Doctor, Dentist, Veterinarian, and local gym/wellness center if they offer PBM therapy and if not, why not.
May 16 is an annual reminder that bringing light therapy into healthcare is long overdue.
It is up to all of us, for ourselves, our families, and our communities, to make the promise of light a reality.
The LIGHTSITE I data was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) annual conference by Marion Munk, MD, PhD, Department of Ophthalmology/Bern Photographic Reading Center and Managing Director, Bern Photographic Reading Center, University Hospital Bern. Dr. Munk was part of the investigator team.
“LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05). Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression,” says Dr. Munk.
“Results from the LIGHTSITE I study following treatment with a multi-wavelength PBM treatment demonstrated clinical improvements in vision outcome measures providing a strong foundation for initial therapy as well as the need for follow-up maintenance therapy,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto. “The PBM therapy was most beneficial in dry AMD patients immediately following the completion of the treatment sessions. Contrast sensitivity or detailed vision was significantly improved throughout the year. Retreatments at a 6 month interval were performed to maintain clinical benefits.”
Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.
Posted inIndustry| on LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data
UK and Ireland dates
USA and Canada dates
Australia and NZ dates
Rest Of World dates
Featured Testimonials
THOR on Facebook
THOR on Twitter
THOR on LinkedIn
THOR on Instagram
THOR on YouTube
Written by Scot Faulkner 